Avoiding The Pitfalls Of LNP And Complex Formulations

Avoiding supply chain gaps and disruptions is paramount, as biopharmaceutical applications work to scale toward commercial production. This is especially crucial during tech transfers, as more complex biotherapeutics, such as lipid nanoparticle-based drugs (LNPs), often require more comprehensive and tightly controlled testing and manufacturing.

In a recent webinar, “Considerations for Complex Formulations: How to Simplify Your Outsourcing,” drug technology innovation and manufacturing experts explored the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.

This article summarizes the insights from the recent webinar and discusses how to be strategic when partnering with a CDMO for complex formulation development.